Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dipyridamole for coronary slow flow phenomenon
ACTRN12606000236594Phase 3Completed
- Sponsor
- The Queen Elizabeth Hospital,Cardiology Unit
- Start
- Oct 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dipyridamole in Slow Coronary Flow (SCF) (2 arms), sponsored by The Queen Elizabeth Hospital,Cardiology Unit. Primary endpoint: Angina frequency. Started Oct 2002; status: completed.
02
Drugs
dipyridamole
03
Conditions
Slow Coronary Flow (SCF)
Beyond the preview
Go deeper on ACTRN12606000236594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000236594.